表在性膀胱腫瘍に対するMitomycin CとAdriamycinの連続膀胱内注入療法(予報)

Abstract

表在性膀胱腫瘍19例に対しMMCとADMの2剤による膀胱内注入療法を施行した.方法は第1日にMMC 20 mg, 第2日にADM 40 mgの注入を毎週, 5週間くり返した.1)評価可能16例中10例(63%)がCR, 2例がPR, 4例がNCであった.2) high gradeの腫瘍, とくに上皮内癌においては7例中CR 6例と高い有効性が認められた.3)副作用は膀胱炎症状が19例中10例(53%)にみられた.このうち高度なものは6例で5例では治療を中止したが, 全例4週以内に症状の消失をみた

Intravesical chemotherapy with sequential instillation of mitomycin C and adriamycin was carried out on 19 patients with superficial bladder cancer (Ta, T1 and Tis). Twenty milligram of mitomycin C on day 1 and 40 mg of adriamycin on day 2 were instilled into the bladder, this treatment being repeated weekly for 5 consecutive weeks if there were no serious side effects. The following results were obtained. Of 16 evaluable patients, 10 patients (63%) achieved complete response and 2 patients achieved partial response, 4 patients showing no response. In patients with high grade tumor, especially with carcinoma in situ, a high CR rate (6/7 or 86%) was achieved. Chemical cystitis occurred in 10 out of 19 (53%) patients. In 5 of the 6 patients who suffered from severe cystitis symptoms, treatment was discontinued. However, the symptoms resolved within 4 weeks in all patients.